S-1: Notable Labs Eyes $15 Million Capital Injection Through Share and Warrant Offering

Notable Labs is seeking to raise up to $15 million through a best-efforts offering of ordinary shares and warrants to fund research and development and general corporate purposes.

Summary

• Notable Labs is launching a best-efforts offering to sell up to 19,736,842 ordinary shares and warrants to purchase an equal number of ordinary shares.
• The combined assumed public offering price is $0.76 per share and accompanying warrant, based on the closing price of the company's ordinary shares on June 18, 2024.
• The company is also offering pre-funded warrants as an alternative to ordinary shares for purchasers who would exceed beneficial ownership limits.
• The exercise price of the ordinary warrants will be determined upon shareholder approval of a charter amendment to increase the number of authorized ordinary shares.
• Maxim Group LLC is acting as the exclusive placement agent for the offering.
• The company intends to use the net proceeds for research and development, general corporate purposes, and potential investments in complementary businesses or technologies.
• The offering is expected to close within two business days following commencement, with delivery versus payment terms.
• The company will pay Maxim Group a cash fee equal to 7.0% of the gross proceeds from non-insiders and 3.5% from company insiders, plus reimbursement of legal fees up to $100,000.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The announcement is a standard capital raise, with both positive and negative aspects. The success of the offering is uncertain, and dilution is a concern, but the funds could help advance the company's pipeline.

Positives

• The offering provides capital to advance research and development efforts.
• Pre-funded warrants offer flexibility for investors concerned about ownership limits.
• The company has engaged Maxim Group LLC as exclusive placement agent.

Negatives

• The offering is on a best-efforts basis, so there is no guarantee the company will raise the full $15 million.
• Existing shareholders will experience dilution.
• The company's management has broad discretion over the use of proceeds.
• There is no established public trading market for the Ordinary Warrants or the Pre-Funded Warrants, and we do not expect a market to develop.

Risks

• The best-efforts structure of the offering may have an adverse effect on the business plan.
• Future sales of ordinary shares may depress the share price.
• The Ordinary Warrants are not exercisable until shareholder approval of the Charter Amendment.
• The market price of our ordinary shares may be highly volatile, and you may not be able to resell your shares at the purchase price.
• Our principal shareholders own a significant percentage of our shares and will be able to exert significant control over matters subject to shareholder approval.
• We do not intend to pay dividends on our ordinary shares in the foreseeable future, so any returns will be limited to the value of our shares.

Future Outlook

The company intends to use the net proceeds from this offering for research and development and general corporate purposes, which may include capital expenditures, working capital and general and administrative expenses, and potential investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements to make any such investments as of the date of this prospectus.

Industry Context

This announcement is typical for a clinical-stage biopharmaceutical company seeking funding to advance its pipeline. The use of a best-efforts offering with warrants is a common structure for smaller companies.

Stakeholder Impact

• Shareholders will experience dilution.
• The company's ability to execute its business plan will be affected by the success of the offering.
• The company's employees and customers may benefit from the advancement of the company's pipeline.

Next Steps

• The company will seek shareholder approval for a charter amendment to increase the number of authorized ordinary shares.
• The company will use the net proceeds from the offering to advance the clinical development of Volasertib in acute myeloid leukemia and for general corporate purposes.

Key Dates

Keywords

ordinary shares, warrants, offering, capital raise, Notable Labs, Maxim Group, pre-funded warrants, NTBL